List of Excipients in Branded Drug ESBRIET

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Genentech Inc	ESBRIET	pirfenidone	50242-121	AMMONIA
Genentech Inc	ESBRIET	pirfenidone	50242-121	CELLULOSE, MICROCRYSTALLINE
Genentech Inc	ESBRIET	pirfenidone	50242-121	CROSCARMELLOSE SODIUM
Genentech Inc	ESBRIET	pirfenidone	50242-121	FERRIC OXIDE RED
Genentech Inc	ESBRIET	pirfenidone	50242-121	FERRIC OXIDE YELLOW
Genentech Inc	ESBRIET	pirfenidone	50242-121	FERROSOFERRIC OXIDE
Genentech Inc	ESBRIET	pirfenidone	50242-121	GELATIN

ESBRIET Excipient Strategy and Commercial Opportunities

Last updated: August 8, 2026

Esbriet, Roche’s pirfenidone product for idiopathic pulmonary fibrosis, has a relatively simple immediate-release formulation. Its commercial vulnerability comes from active-ingredient commoditization, generic competition, substantial daily pill burden, gastrointestinal tolerability, and the absence of a strong excipient-based differentiation platform. The best opportunities are in swallowability, dosing convenience, gastrointestinal performance, global formulation compliance, and lifecycle products that can obtain separate regulatory and patent protection.

What is Esbriet and how is it formulated?

Esbriet contains pirfenidone, a small-molecule antifibrotic approved in the United States in 2014 for adults with idiopathic pulmonary fibrosis. The US product is available as 267 mg capsules and 801 mg tablets. The recommended maintenance dose is 801 mg three times daily, or 2,403 mg per day.[1]

The formulation is an immediate-release oral solid dosage form. The label does not identify a specialized controlled-release delivery system, lipid vehicle, enteric coating, or amorphous solid dispersion.

Esbriet excipients by dosage form

Dosage form	Strength	Core excipients	Coating or shell materials
Capsule	267 mg	Microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, sodium lauryl sulfate	Gelatin shell, titanium dioxide, yellow iron oxide, black iron oxide
Film-coated tablet	801 mg	Microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate	Polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, yellow iron oxide

The capsule formulation uses conventional direct-compression or dry-granulation excipient technology. Microcrystalline cellulose provides bulk and compaction. Croscarmellose sodium promotes disintegration. Colloidal silicon dioxide improves flow, while magnesium stearate supports lubrication. Sodium lauryl sulfate functions as a wetting agent and can assist dissolution of the poorly water-soluble pirfenidone molecule.[1]

The 801 mg tablet reduces the number of units required at maintenance dosing. Patients taking the labeled regimen use three 801 mg tablets per day rather than nine 267 mg capsules. That difference creates a commercial advantage for high-dose tablets but does not eliminate the broader pill-burden problem.

What excipient constraints affect pirfenidone formulation?

Pirfenidone is a low-molecular-weight, orally active drug with limited aqueous solubility. Its development priorities are dissolution, dose uniformity, manufacturability, chemical stability, and gastrointestinal tolerability.

Solubility and dissolution

The existing use of sodium lauryl sulfate in the capsule formulation indicates a need to manage wetting or dissolution performance. A generic or follow-on manufacturer can examine alternative surfactants, including poloxamers, sodium stearyl fumarate, sodium docusate, or selected nonionic surfactants. Each substitution creates regulatory comparability requirements and may affect impurity formation, tablet strength, disintegration, or food-related exposure.

A formulation that improves dissolution without materially increasing systemic exposure may provide a practical development path. A formulation that increases exposure could create safety and bioequivalence problems, particularly because pirfenidone is administered at a high total daily dose.

High-dose tablet engineering

An 801 mg pirfenidone tablet must maintain acceptable tablet weight, hardness, friability, disintegration, and swallowability. Large tablets can create adherence problems in older patients, who represent a major part of the idiopathic pulmonary fibrosis population.

Commercial opportunities include:

• Smaller multiparticulate units packaged as sachets or capsules.
• Orally disintegrating tablets.
• Mini-tablets administered in a capsule or sprinkle format.
• Granules for suspension.
• Bilayer or multilayer tablets that separate functional excipient systems.
• High-density tablets that reduce overall volume without compromising disintegration.

These approaches may require a new clinical bridge or a drug-device or drug-product development program. They also create opportunities for formulation patents directed to particle size, excipient ratios, coating systems, disintegration time, dissolution profiles, or dose administration.

Which excipient strategies could improve Esbriet tolerability?

Gastrointestinal adverse events are commercially important for pirfenidone. The US label identifies nausea, rash, dyspepsia, diarrhea, and photosensitivity among common adverse reactions. Taking Esbriet with food is recommended because food reduces the rate of absorption and may improve tolerability.[1]

Food-compatible delivery

A formulation that reproduces the food-associated reduction in absorption rate could support a differentiated product. Possible approaches include:

• Hydrophilic matrix systems that slow dissolution.
• Lipid-based formulations that reduce peak concentration.
• Polymer-coated multiparticulates.
• Delayed-release or pulsatile systems.
• Gastric-retentive formats, although these carry substantial development complexity.

The most commercially credible strategy is a moderate-release formulation that reduces peak-related gastrointestinal symptoms while preserving total exposure. The regulatory burden increases materially if the product changes the pharmacokinetic profile or dosing schedule.

Gastrointestinal protection

Enteric protection is less straightforward because the product is already administered with food and because delayed gastric release could alter exposure. A gastric-protective coating, mucoadhesive system, or microencapsulation approach could reduce local irritation, but the formulation must demonstrate equivalent or clinically acceptable exposure.

A manufacturer could pursue a product positioned for patients who discontinue immediate-release pirfenidone because of nausea or dyspepsia. That opportunity has greater commercial value than a minor manufacturing improvement, but it also requires evidence linking the formulation to adherence or tolerability.

What formulation patents could protect an Esbriet follow-on product?

Formulation patents can protect technical features that are distinct from the expired or expiring pirfenidone active-ingredient claims. The strongest claim categories would include:

Patent category	Potential protected subject matter	Commercial value
Particle engineering	Defined particle-size distribution, crystallinity, or morphology	Moderate
Dissolution enhancement	Surfactant, polymer, or co-processing system	Moderate to high
Modified release	Matrix, coating, multiparticulate, or delayed-release system	High if clinically useful
Swallowability	Mini-tablets, granules, orally disintegrating dosage forms	Moderate
Stability	Excipient combination that limits degradation or discoloration	Moderate
Administration method	Food-linked dosing or titration regimen	Variable
Combination therapy	Pirfenidone with antifibrotic or supportive-care agents	High, but clinically complex
Manufacturing process	Continuous processing, granulation, compression, or coating parameters	Moderate

Patent strength depends on whether the claim requires a genuine technical effect. A broad claim covering pirfenidone plus a conventional excipient is vulnerable to enablement, written-description, obviousness, and anticipation challenges. Claims tied to a measured dissolution profile, pharmacokinetic effect, improved tolerability, or validated stability advantage are more defensible.

A manufacturer should separate patent families for formulation composition, manufacturing process, and clinical use. This structure improves licensing flexibility and can support different markets or product presentations.

When does Esbriet lose exclusivity and what is the generic risk?

Pirfenidone’s core small-molecule exclusivity is substantially weaker than it was during the original Esbriet launch period. The product is not a biologic, so biosimilar substitution is not the relevant competitive pathway. The main risks are ANDA-based generic entry and product-specific formulation competition.

The FDA approved Esbriet in 2014. The product’s five-year new chemical entity exclusivity expired in 2019, subject to statutory details and any applicable patent litigation or pediatric extensions.[1] Core composition-of-matter patent protection for pirfenidone has also expired or reached the end of its principal term in the United States. Later patents may cover treatment methods, dosing, or specific formulations, and those patents must be assessed through current FDA Orange Book and USPTO records.[2,3]

Paragraph IV challenges

A generic applicant can file an ANDA with a Paragraph IV certification against listed patents. The brand holder may then bring an infringement action within 45 days, triggering a statutory stay of FDA approval for up to 30 months, subject to court decisions and statutory exceptions.

For Esbriet, the commercial risk is highest where:

• The ANDA relies on the same immediate-release dosage form.
• The generic can demonstrate bioequivalence using standard pharmacokinetic studies.
• Listed patents do not cover the generic’s excipients or manufacturing process.
• The remaining patents are method-of-use claims that are difficult to enforce against a label with carved-out indications.
• Several generic applicants enter or prepare launch simultaneously.

The 801 mg tablet may be more attractive to generic manufacturers because it reduces unit count and avoids the manufacturing and encapsulation requirements associated with the 267 mg capsule. The capsule remains relevant for dose titration and lower-dose administration.

What is the Orange Book status of Esbriet?

The Orange Book is the controlling FDA source for listed patents, pediatric exclusivity, therapeutic-equivalence evaluations, and approved products.[2] Esbriet’s relevant Orange Book analysis should distinguish:

1. Active ingredient claims.
2. Formulation claims.
3. Method-of-use claims.
4. Product-by-process or manufacturing claims, if listed.
5. Pediatric exclusivity or other statutory extensions.
6. Approved capsule and tablet presentations.

An Orange Book listing does not establish that a patent will survive litigation. It determines the certification and litigation framework for an ANDA applicant. The commercial question is whether a generic can launch after a successful invalidity or noninfringement decision, a settlement date, a court-approved license, or the expiration of the relevant patent barrier.

How strong is the Esbriet patent estate?

The estate is strategically weaker than a biologic patent estate or a product with multiple device and formulation layers. Pirfenidone is a conventional small molecule, and the marketed dosage forms use widely available excipients.

Strengths

• Established regulatory history and clinical exposure.
• Multiple dosage forms, including a high-strength tablet.
• Potential method-of-use and dosing claims.
• Possible formulation and manufacturing patents around modified release or tolerability.
• Clinical value in a chronic, high-morbidity disease.

Weaknesses

• Conventional excipient platform.
• No complex delivery device.
• High probability of standard oral-solid-dose generic approaches.
• Limited ability to block generic entry through routine excipient substitutions.
• Difficulty enforcing method-of-use claims against a carved-out generic label.

The strongest lifecycle strategy is therefore a clinically differentiated formulation, not a minor excipient swap. A product must provide measurable value through fewer daily units, improved tolerability, reduced food dependence, easier administration, or improved adherence.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can participate at several points in the pirfenidone value chain.

High-value opportunities

A supplier with a proprietary co-processed excipient, solubilization platform, or modified-release polymer system could target generic manufacturers and lifecycle-product developers. The most attractive commercial propositions are:

• Improved dissolution at lower surfactant concentration.
• Better flow and compaction for the 801 mg tablet.
• Lower tablet weight.
• Faster disintegration without capping or lamination.
• Improved stability under humidity and temperature stress.
• Taste masking for liquid, sprinkle, or orally disintegrating formats.
• Consistent performance across global manufacturing sites.

Lower-value opportunities

Commodity replacement of microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate, or croscarmellose sodium is unlikely to create durable pricing power. These materials are widely available, and substitution is generally possible unless the product has a narrow process window.

Excipient suppliers can still gain share by offering:

• Multisite supply.
• Pharmaceutical-grade documentation.
• Change-control support.
• Nitrosamine and elemental-impurity assessments.
• Direct compression performance.
• Regulatory packages for multiple jurisdictions.
• Technical support during bioequivalence and scale-up.

How does Esbriet compare with Ofev?

Esbriet and Ofev are the two principal antifibrotic products for idiopathic pulmonary fibrosis. Ofev contains nintedanib and is marketed by Boehringer Ingelheim. Both products are oral and require chronic administration, but their excipient and lifecycle strategies differ.

Attribute	Esbriet	Ofev
Active ingredient	Pirfenidone	Nintedanib
Product type	Small molecule	Small molecule
Main dosage burden	Three-times-daily dosing	Twice-daily dosing
Key formulation issue	High daily pill burden, food-linked tolerability	Gastrointestinal tolerability and oral solid performance
Biosimilar risk	None	None
Generic risk	ANDA and formulation competition	ANDA and formulation competition
Differentiation opportunity	Modified release, swallowability, adherence	Dose flexibility, tolerability, delivery and combination products

Esbriet has a larger convenience gap because of three-times-daily dosing. That makes modified-release pirfenidone commercially attractive, even if development and regulatory requirements are significant.

What generic launch scenarios exist for Esbriet?

Three launch scenarios are commercially relevant.

Early launch after patent challenge

A generic applicant challenges listed patents and launches after a favorable court ruling or settlement license. Price erosion can be rapid, particularly if several applicants launch within a short period.

Authorized generic or licensed entry

The brand owner licenses a generic or launches an authorized generic. This can preserve some volume while reducing the price shock from independent competitors.

Delayed generic erosion through lifecycle reformulation

A differentiated modified-release or adherence-oriented product launches before broad generic substitution. The brand shifts patients to the protected formulation, while the original capsule and tablet products face price erosion.

The third scenario provides the strongest excipient-driven opportunity, but only if the reformulated product receives meaningful clinical or adherence support and gains market access.

Key Takeaways

• Esbriet uses conventional excipients in 267 mg capsules and 801 mg film-coated tablets.
• The main formulation weaknesses are three-times-daily dosing, gastrointestinal tolerability, and high cumulative pill burden.
• The highest-value excipient opportunities involve modified release, dissolution control, smaller dosage units, and improved swallowability.
• Commodity excipient substitution is unlikely to create durable commercial differentiation.
• Pirfenidone has no biosimilar risk; generic ANDA competition is the primary threat.
• Formulation patents should focus on measurable technical effects, including dissolution, pharmacokinetics, stability, or tolerability.
• The 801 mg tablet is the most commercially efficient existing presentation, but a lower-burden modified-release product could be more valuable.
• Current Orange Book, USPTO, FDA litigation, and settlement records control the precise remaining patent barriers.

FAQs

Can a generic manufacturer copy Esbriet’s excipients?

A generic manufacturer can generally use different inactive ingredients if the product meets FDA quality, safety, dissolution, and bioequivalence requirements. The generic does not need to duplicate every excipient in the reference product.

Which excipient is most important for pirfenidone dissolution?

Sodium lauryl sulfate is the most conspicuous dissolution-oriented excipient in the 267 mg capsule, but its role must be evaluated with the complete formulation and manufacturing process. Alternative wetting and solubilization systems may be viable.

Could pirfenidone be developed as a once-daily product?

A once-daily product would require a modified-release formulation with appropriate exposure over 24 hours. It would likely require substantial formulation, pharmacokinetic, clinical, and regulatory development.

Are Esbriet formulation patents stronger than its active-ingredient patents?

Formulation patents can remain valuable after active-ingredient patents expire, but their strength depends on claim specificity and demonstrated technical effects. Conventional excipient combinations are generally more vulnerable to obviousness challenges.

Is an Esbriet liquid formulation commercially attractive?

A liquid or suspension could address swallowing limitations, but pirfenidone’s high daily dose creates challenges in taste masking, dosing volume, chemical stability, preservative selection, packaging, and patient convenience.

References

1. U.S. Food and Drug Administration. (2023). Esbriet (pirfenidone) prescribing information. Genentech, Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. United States Patent and Trademark Office. (2024). Patent Center. https://patentcenter.uspto.gov/

4. U.S. Food and Drug Administration. (2014). FDA approves Esbriet to treat idiopathic pulmonary fibrosis. https://www.fda.gov/

5. Roche Holding AG. (2023). Annual report 2023. Roche.